Clinical Trials Logo

Moderate Depression clinical trials

View clinical trials related to Moderate Depression.

Filter by:

NCT ID: NCT06336538 Not yet recruiting - Breast Cancer Clinical Trials

Abbreviated MBCT for Depression in Older African American/Black Breast Cancer Survivors

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

The purpose of this research study is to develop and test an intervention designed to improve mood and reduce symptoms of depression.

NCT ID: NCT06112652 Recruiting - Clinical trials for Major Depressive Disorder

Neuromodulation of Different Doses to Treat TRD Guided by pBFS Technique

Start date: December 4, 2023
Phase: N/A
Study type: Interventional

The aim of this study is to explore the effectiveness and safety of different doses of neural regulation under the guidance of pBFS technology in improving symptoms in patients with moderate to severe depressive disorders.

NCT ID: NCT06005103 Recruiting - Moderate Depression Clinical Trials

T-PEMF Headband Stimulation for Patients With Moderate to Servere Depression

Start date: June 6, 2023
Phase: N/A
Study type: Interventional

This study is a blinded 8-week, randomized trial conducted to clarify whether treatment with brain stimulation for half an hour daily for eight weeks with a headband with weak pulsating electromagnetic fields (T-PEMF) can achieve a safe effect on depression compared to the same treatment with a placebo T-PEMF.

NCT ID: NCT05957341 Not yet recruiting - Clinical trials for Major Depressive Disorder

pBFS Guided 20min Inter-session Interval rTMS Treatment for MDD

Start date: July 30, 2023
Phase: N/A
Study type: Interventional

The investigators aim to explore the efficacy and safety of rTMS therapies with different intervals between sessions for treating patients with moderate to severe depression.

NCT ID: NCT05842278 Recruiting - Clinical trials for Major Depressive Disorder

The Dosage Effect of pBFS Guided rTMS Treatment for MDD

Start date: July 7, 2023
Phase: N/A
Study type: Interventional

The investigators aim to find the optimal dosage of the pBFS-guided rTMS treatment for patients with moderate to severe depression.

NCT ID: NCT05594667 Withdrawn - Depression Clinical Trials

Effect of SSRIs on Response to Psilocybin Therapy

Start date: January 1, 2023
Phase: Phase 2
Study type: Interventional

This study is an open-label, single-arm, within-subjects design in individuals with mild-moderate Major Depressive Disorder (MDD). All participants will receive a single dose of 25mg of psilocybin in a therapeutic setting. In order to investigate the effects of length of time on SSRI therapy, 30 participants with varying lengths of time on SSRI therapy will be enrolled, stratified into four groups: - Group 1: ≤ 1 year - Group 2: 1 to ≤ 5 years - Group 3: 5 to ≤ 10 years - Group 4: > 10 years

NCT ID: NCT05551702 Active, not recruiting - Moderate Depression Clinical Trials

Treating Depression With Text Messaging

Start date: July 6, 2022
Phase: N/A
Study type: Interventional

The purpose of the research study is to investigate whether CBT-txt, a counseling program delivered by text messages is effective in stopping or reducing depressive symptoms. CBT-txt is based on a counseling program that has been proven to reduce depression when delivered in-person and on the web, but has not yet been tested or shown to be effective when delivered by text.

NCT ID: NCT05386745 Completed - Low Mood Clinical Trials

Feasibility Study of an Online Physical Activity Intervention for Youth With Depression

Start date: February 22, 2022
Phase: N/A
Study type: Interventional

Physical activity (PA) has recently been established as both a primary intervention for mild to moderate, and a secondary therapy for moderate to severe Major Depressive Disorder (MDD; Fortier et al., 2020). Those with mental health disorders do not on average achieve recommended levels of PA (Hallgren et al., 2016), and exercise prescription is extremely lacking in clinical care (Stanton, Reaburn, & Happell, 2015; Stanton et al., 2018). Theory-based behavioural interventions have proven to be an effective tool for improving physical activity levels in clinical populations (Glowacki, et al., 2017; Stanton et al., 2015). More research is needed to understand PA intervention effectiveness for MDD patients (Glowacki et al., 2017), support integration of such behavioural treatments with primary care (Lederman et al., 2017), and address growing concerns regarding mental health during the global pandemic and beyond (Boyce, 2021). This community-based study examines the feasibility of a co-designed, 10-week, asynchronous, web-based beta platform PA intervention for patients with experience of low mood and/or mild to moderate depression, and will provide important parameters for a future randomized-controlled trial (RCT). Primary outcome measures will focus on acceptability and feasibility, including recruitment and retention rates. Secondary measures will include physical activity and depression symptom severity. Behavioural predictors of PA are to be evaluated as tertiary outcomes. Questionnaires will include an adapted participant experience measure, Godin Leisure-Time Exercise Questionnaire, and the Patient Health Questionnaire-9. This study features a controlled baseline, post-intervention evaluative design with an embedded quantitative process evaluation with a waitlist control. Participants will be young adults with experience of low mood and/or mild to moderate depression, 19-30 years of age, with access to a device with internet, English speaking, living within British Columbia, CAN., and falling below the minimum Canadian recommendations for PA. Study recruitment will primarily be facilitated by multiple youth mental health primary and community care clinics. This study will contribute to understanding of acceptable, efficacious, behaviour-based and mobile health intervention approaches for young adults with depression. It will also provide young people with a platform to share invaluable feedback to direct innovations in their own alternative care and mental health treatment. If outcome benchmarks set based on previous literature are met or exceeded for each of recruitment, retention, and acceptability, and depressive symptoms trend downwards for intervention participants, then a future randomized controlled trial exploring principally mental health outcomes will be recommended.

NCT ID: NCT04766242 Not yet recruiting - Moderate Depression Clinical Trials

The Impact of Spiritual Healing on Moderate Depression in Adults

Start date: March 1, 2021
Phase: N/A
Study type: Interventional

Depression is a common mental disorder and is together with anxiety the global leading cause of all non-fatal burden of disease. Currently supported treatment for depression is antidepressant medication and different psychotherapeutic interventions. Many patients experience, however, adverse effects of antidepressant medication, while at the same time the access to psychotherapeutic interventions are limited. This is particularly the case for patients suffering from moderate depression. Many patients who suffer from depression turn to complementary and alternative medicine (CAM), and among those therapies often spiritual healing. There is some evidence that consulting a spiritual healer can be beneficial for patients suffer from depression, and that spiritual healing is associated with low risk. The objective of this study is therefor to conduct a pilot RCT (spiritual healing as addition to usual care versus usual care alone) in preparation of a larger trial in adults with moderate depression to examine feasibility and individuals' experience of spiritual healing. This study is a pilot randomized controlled trial (RCT) with two parallel groups. A total of 28 adult patients with moderate depression according to the M.I.N.I. PLUS DSM-V criteria will be randomized to spiritual healing in addition to usual care intervention (n=14) or usual care alone (n=14). Ten treatment sessions (lasting 45-60 minutes each) of spiritual healing will be administered as an adjunct to usual care and compared to usual care alone. Reduction in depression symptoms will be measured with Beck Depression Inventory (BDI) and Montgomery and Åsberg Depression Rating Scale (MADRS) collected at baseline, week 8 and 16, in addition to BDI measurement collected 6 and 12 months after inclusion in the study. To investigate participants' experience with spiritual healing, a qualitative study will be included using a phenomenological hermeneutical method and semi-structured interviews.

NCT ID: NCT03060200 Completed - Moderate Depression Clinical Trials

Reducing Depressive Symptomatology With a Smartphone App

Start date: February 17, 2017
Phase: N/A
Study type: Interventional

The aim of this study is to test a newly developed app, firmly grounded in Cognitive Behavioural Therapy (CBT) theory of depression, to determine primarily if this app is clinically useful in decreasing moderate depressive symptoms when compared with an active placebo. Additionally, we are interested in the app's potential to contribute to the reduction of general negative affect, increasing positive affect, and boosting satisfaction with life. Last, but not least, we aim to verify if the usage of the tested app can modify depressogenic cognitions.